With long-awaited biosimilar competition to AbbVie’s top-selling Humira (adalimumab) brand finally expected to hit the US in 2023, the off-patent industry is bracing for its biggest ever loss-of-exclusivity opportunity.
Humira In 2023: The $17bn Biosimilar Opportunity
Landmark LOE Looms In US; Several Adalimumab Launches Expected Throughout Year
The advent of US biosimilar competition to Humira in 2023 represents the largest ever loss-of-exclusivity opportunity for the off-patent industry, with the first adalimumab rival expected to hit the US market at the end of this month. But with a host of other biosimilars expected to launch throughout the year, how will competition play out in the long term?
More from Biosimilars
More from Products
• By
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
• By
With discounts reaching up to 90%, ustekinumab biosimilars have eroded originator Stelara’s sales as expected. In its latest quarterly biosimilar market report, Samsung Bioepis also analyzed the latest regulatory steps to streamline biosimilar development.
• By
As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.